Exercise to prevent shoulder problems in patients undergoing breast cancer treatment

Submission date Recruitment status [X] Prospectively registered 23/01/2015 No longer recruiting [X] Protocol [] Statistical analysis plan Registration date Overall study status 04/02/2015 Completed [X] Results Individual participant data **Last Edited** Condition category 02/03/2023 Cancer

Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-to-prevent-shoulder-problems-after-breast-cancer-treatment-prosper

Study website

www.warwick.ac.uk/go/prosper

Contact information

Type(s)

Public

Contact name

Mrs Lauren Betteley

Contact details

Warwick Clinical Trials Unit Warwick Medical School Gibbet Hill Road Coventry United Kingdom CV4 7AL +44 (0)2476 551722 prosper@warwick.ac.uk

Type(s)

Scientific

Contact name

Dr Julie Bruce

ORCID ID

http://orcid.org/0000-0002-8462-7999

Contact details

Warwick Clinical Trials Unit Warwick Medical School Gibbet Hill Road Coventry United Kingdom CV4 7AL +44 (0)2476 151128 julie.bruce@warwick.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers HTA 13/84/10

Study information

Scientific Title

The PRevention Of Shoulder Problems Study (PROSPER): a randomised controlled clinical trial comparing physiotherapy-led exercise versus usual care in women at high risk of shoulder problems after breast cancer surgery

Acronym

PROSPER

Study objectives

The hypothesis for the study is that an early supervised exercise programme delivered to women at high risk of subsequent shoulder problems after breast cancer surgery, can improve upper arm function and health-related quality of life, reduce disability, pain and other adverse events, 12 months after treatment.

The overall aim of the study is to investigate the clinical and cost-effectiveness of early supervised exercise compared to usual care, on outcomes of shoulder/arm function, chronic pain and health-related quality of life after treatment for breast cancer.

More details can be found at: http://www.nets.nihr.ac.uk/projects/hta/138410 Protocol can be found at: http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0010/136999/PRO-13-84-10.pdf

Ethics approval required

Old ethics approval format

Ethics approval(s)

West Midlands – Solihull Research Ethics Committee, 20/07/2015, ref: 15/WM/0224

Study design

Multicentre randomised controlled clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Community

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Breast cancer surgery

Interventions

Intervention:

A physiotherapy-led exercise programme incorporating behavioural strategies. The intervention package will involve different phases to encourage early restricted movement, progression of exercises to incorporate range of motion and strengthening, followed by a maintenance phase to ensure that flexibility and strength are maintained over time.

Control group:

Best practice usual care.

Intervention Type

Behavioural

Primary outcome measure

Arm, shoulder and hand function measured using the Disability of the Arm, Shoulder and Hand (DASH) questionnaire at 12 months (0=no functional problems, 100=maximal problems)

Secondary outcome measures

- 1. Assessment of arm, shoulder and hand function (DASH) subscales measured at baseline, 6 and 12 months
- 2. Health-related QoL as measured by SF-12 & EQ-5D-5L, measured at baseline, 6 and 12 months
- 3. Acute and chronic postoperative pain measured using pain items from DASH and Doleur Neuropathique (DN4) to capture neuropathic pain, measured at baseline, 6 weeks, 6 and 12 months
- 4. Surgical site infection measured at 6 weeks (clinical criteria)
- 5. Postoperative symptoms including indicators of lymphoedema at 6 and 12 months (DASH and

lymphoedema screening items [Armer et al., 2003])

6. Healthcare resource use measured at 6 and 12 months (self-report)

Overall study start date

01/03/2015

Completion date

14/03/2020

Eligibility

Key inclusion criteria

Inclusion criteria as of 31/03/2016:

- 1. Women, age > 18 years
- 2. Histologically confirmed invasive or non-invasive primary breast cancer scheduled for surgical excision
- 3. Considered high risk of developing shoulder problems after surgery, defined by one or more of the following:
- 3.1. Planned axillary node clearance (ANC)
- 3.2. Planned radiotherapy (RT) to axilla and/or supraclavicular
- 3.3. Existing shoulder problems (based upon PROSPER screening criteria)
- 3.4. Obesity defined as BMI >30
- 3.5. Any subsequent axillary surgery related to primary surgery e.g. ANC conducted after sentinel lymph node biopsy
- 4. Willing and able to comply with the protocol
- 5. Written informed consent
- 6. Any later decision (made within 6 weeks of surgery) to refer for RT to axilla and/or supraclavicular

Note:

- 1. Women who have had previous breast surgery (e.g. excision of benign tumour or breast cyst) are eligible for invitation
- 2. Women who have had previous contralateral (opposite side) mastectomy are eligible for invitation

Original inclusion criteria:

- 1. Female ≥ 18 years, no upper age limit
- 2. Histologically confirmed invasive or non-invasive early breast cancer scheduled for surgical excision of breast cancer
- 3. Predicted high risk of developing shoulder problems post breast cancer surgery (existing shoulder problems/planned axillary surgery/radiotherapy)
- 4. Willing and able to comply with the protocol

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

350

Total final enrolment

392

Key exclusion criteria

Exclusion criteria as of 31/03/2016:

- 1. Males
- 2. Women having immediate reconstructive surgery
- 3. Women having sentinel lymph node biopsy (SLNB) with or without breast surgery unless have other high risk criteria
- 4. Women having bilateral breast surgery
- 5. Evidence of known metastatic disease at time of recruitment

Original exclusion criteria:

- 1. Males with breast cancer
- 2. Major psychiatric disorder or psychological disorder, including substance abuse that would preclude engagement with the programme
- 3. Detectable metastatic disease
- 4. Planned immediate reconstructive surgery
- 5. Bilateral breast surgery

Date of first enrolment

01/10/2015

Date of final enrolment

31/07/2017

Locations

Countries of recruitment

England

United Kingdom

Study participating centre University Hospitals Coventry & Warwickshire NHS Trust

Clifford Bridge Road Coventry United Kingdom CV2 2DX

Study participating centre Oxford University Hospitals NHS Foundation Trust

Churchill Hospital Old Road Oxford Oxford United Kingdom OX3 7LE

Study participating centre The Royal Wolverhampton NHS Trust

New Cross Hospital Wednesfield Road Wolverhampton United Kingdom WV10 0QP

Study participating centre Walsall Healthcare NHS Trust

Walsall Manor Hospital Moat Road Walsall United Kingdom WS2 9PS

Study participating centre Chesterfield Royal Hospital NHS Foundation Trust

Calow Chesterfield United Kingdom S44 5BL

Study participating centre The Hillingdon Hospitals NHS Foundation Trust

Hillingdon Hospital Pield Heath Road Uxbridge United Kingdom UB8 3NN

Study participating centre

Royal Blackburn Hospital

East Lancashire Hospitals NHS Trust Haslingden Road Blackburn United Kingdom BB22 3HH

Study participating centre East Lancashire Hospitals NHS Trust

Royal Blackburn Hospital Haslingden Road Blackburn United Kingdom BB2 3HH

Study participating centre Birmingham City Hospital, Sandwell & West Birmingham NHS Trust

Birmingham City Hospital
Dudley Road
Birmingham
United Kingdom
B18 7QH

Study participating centre

Dorset County Hospital NHS Foundation Trust

Dorset County Hospital Williams Avenue Dorchester Dorset United Kingdom DT1 2JY

Study participating centre George Elliot Hospital NHS Trust

College Street Nuneaton Warwickshire Nuneaton United Kingdom CV10 7DJ

Study participating centre Hereford County Hospital Wye Valley NHS Trust

Stonebow Road Hereford United Kingdom HR1 2BN

Study participating centre Macclesfield District General Hospital

East Cheshire NHS Trust Victoria Road Macclesfield United Kingdom SK10 3BL

Study participating centre Milton Keynes University Hospital NHS Foundation Trust

Standing Way Milton Keynes United Kingdom MK6 5LD

Study participating centre Musgrove Park Hospital

Taunton & Somerset NHS Foundation Trust Parkfield Road Taunton Somerset United Kingdom TA1 5DA

Study participating centre Queen Alexandra Hospital

Portsmouth Hospitals and Solent NHS Trust Southwick Hill Road Portsmouth United Kingdom PO6 3LY

Study participating centre

Royal Cornwall Hospitals NHS Trust

Treliske Truro United Kingdom TR1 3LJ

Study participating centre Royal Stoke University Hospitals

Newcastle Road Stoke-on-Trent United Kingdom ST4 6QG

Sponsor information

Organisation

University of Warwick

Sponsor details

University House Kirby Corner Road Coventry England United Kingdom CV4 8UW

Sponsor type

University/education

Website

http://www2.warwick.ac.uk/

ROR

https://ror.org/01a77tt86

Organisation

University Hospitals Coventry & Warwickshire NHS Foundation Trust

Sponsor details

University Hospital Clifford Bridge Road Coventry England United Kingdom CV2 2DX

Sponsor type

Hospital/treatment centre

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The results of this trial will inform clinical practice on the identification and management of women at risk of shoulder conditions after breast cancer surgery. In addition to the main HTA report, results will be published in peer-reviewed journals and presented at scientific meetings. We intend to publish the trial protocol in an open access journal (e.g., BioMed Central or BMJ Open).

Intention to publish date

30/06/2020

Individual participant data (IPD) sharing plan

Not provided at registration.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	23/03/2018		Yes	No
Other publications	intervention development	18/06/2018		Yes	No
Results article	qualitative results	11/05/2021	13/05/2021	Yes	No
Results article		10/11/2021	12/11/2021	Yes	No
Plain English results		23/11/2021	23/11/2021	No	Yes
Results article		01/02/2022	01/03/2022	Yes	No
Plain English results			02/03/2023	No	Yes
HRA research summary			28/06/2023	No	No